News Center

Home page

Peak Report

News reports

Announcement on Subsidiary Companies Participating in the Fourth Batch of National Drug Centralized Procurement to be Bwon

Release time:

2021-05-20

Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Lin 2021-003

Zhejiang Jianfeng Group Co., Ltd.

Announcement

on Subsidiaries Participating in the Fourth Batch of National Centralized Drug Procurement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.

On February 3, 2021 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), participated in the fourth batch of national centralized drug procurement bids organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"), peak Pharmaceutical's Olopatadine Hydrochloride Eye Drops is proposed to win the bid for this centralized procurement. The relevant information is hereby announced as follows:

Basic Situation of 1. Proposed Winning Products

Proposed Winning Products

Specifications

Indications

Proposed Winning Price

Proposed Winning Quantity

Provinces

Olopatadine Hydrochloride Eye Drops

5ml:5mg

(0.1%)

is suitable for treating signs and symptoms of allergic conjunctivitis

19.9 yuan/ box

36.23 box

Shanghai, Zhejiang, Guangdong, Sichuan, Henan, Liaoning, Hubei, Chongqing, Hunan, Shaanxi, Anhui, Hainan, Xinjiang (including bingtuan), Jiangxi, Qinghai, Tibet

the bid price and the bid quantity of the above varieties are subject to the final data released by the joint procurement office. According to the relevant winning rules, the bid period for this bid is 1 year.

The impact of 2.'s proposed winning the bid on the company

Jianfeng Pharmaceutical's proposed winning product Olopatadine Hydrochloride Eye Drops obtained the approval of State Drug Administration and issued Drug Registration Approval Document in 4 in 2019 . The market sales volume of was relatively small before , the sales revenue of this product in 2019 and 2020 1-9 September are 5.65 .01 million yuan and 97.74 .03 million yuan respectively, accounting for 2019 annual operating revenue 354 respectively, 753.76 .07 million yuan of 0.0016% and 2020 1-9 March operating income 224,065.44 .15 million yuan of 0.04% .

This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the drugs selected in this centralized drug procurement and ensure the completion of the agreed procurement volume. The price of the products to be selected this time has decreased to a certain extent compared with the original price. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product, increase market share, and enhance the company's brand influence, which has a positive impact.

3. Risk Alert

At present, the company has signed the "Memorandum of National Drug Centralized Procurement of Selected Varieties" with the Joint Procurement Office. There is still uncertainty about the follow-up matters such as the signing of the purchase agreement for the above products and the impact on the company's future performance. The company will pay close attention to the progress of the matter and timely discharge of information disclosure obligations, so that the majority of investors cautious decision-making, pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

February 5, 2001

More information

2022 China's Top 100 Building Materials Enterprises 2022 China's Top 100 Cement Clinker Production Capacity Peak even on two authoritative lists

In March, the authoritative organization of the cement industry successively released two series of lists of China's top 500 building materials enterprises in 2022 and China's top 100 cement clinker production capacity in 2022. Jianfeng Group ranked among the "top 100" in the two lists ". The list of China's top 500 building materials enterprises was officially released in early March. This series of lists was selected by the China Building Materials Enterprise Management Association. Through more than 20 years of comprehensive data research on China's building materials industry, referring to international practices, the rankings are based on the company's annual operating income., Cement products, building ceramics, waterproof materials, aluminum-plastic profiles, coatings, glass, building materials equipment manufacturing and other sub-industries related to building materials. Jianfeng Group ranks 96th among the companies on the list and 27th among the cement manufacturers on the list. On March 16, the awarding ceremony of 2022 China's top 100 cement clinker production capacity list was held in Hangzhou. This series of lists is released by China Cement Network, an authoritative organization in China's cement industry. The ranking is based on the total production capacity (excluding the production capacity of other kiln types and grinding stations) of new dry clinker production lines completed and put into operation by Chinese cement enterprises in China as of December 31, 2022. The data statistics are calculated based on the design production capacity and 310 days of annual operation. Jianfeng Group ranked 53rd with an annual design capacity of 3.627 million tons. (this newspaper reporter)

2023

03-21

Company sends off retired employees

On the morning of February 22, the trade union of the group company held a simple and warm farewell party for retired employees in 2021-2022. More than 50 retired employees gathered together to discuss and exchange with Jiang Xiaomeng and other group leaders.

2023

03-04

On the first day of the new year, group leaders went to the grassroots level.

On January 29, the first day of work after the Spring Festival holiday, the leaders of the group company made a video connection to subordinate enterprises stationed abroad, and separately visited the gold enterprises to learn about the resumption of work and put forward requirements for the implementation of the work plan for the new year.

2023

02-17

Group Companies Commend 2022 Advanced

On the morning of January 18, the group company held the 2022 annual summary commendation meeting to review the work of the previous year, make arrangements for the work in 2023, sign the 2023 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2022 advanced collectives and individuals.

2023

01-29

Jiang Xiaomeng re-elected chairman of the Municipal Federation of Industry and Commerce

On December 24, 2022, the Jinhua Federation of Industry and Commerce (General Chamber of Commerce) held the seventh member representative meeting. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, was re-elected as the chairman of the Municipal Federation of Industry and Commerce at this meeting.

2023

01-12

Peak Pharmaceutical Donates Epidemic Prevention Materials

Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 200,000 yuan.

2023

01-12

< 1 2 3 4...61 > 跳转到页